ADPT:NSD-Adaptive Biotechnologies Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 17.17

Change

-0.35 (-2.00)%

Market Cap

USD 2.47B

Volume

1.17M

Avg Analyst Target

USD 45.00 (+162.09%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Adaptive Biotechnologies Corporation (ADPT) Stock Analysis:
Based on the Adaptive Biotechnologies Corporation stock forecasts from 3 analysts, the average analyst target price for Adaptive Biotechnologies Corporation is USD 45.00 over the next 12 months. Adaptive Biotechnologies Corporation’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Adaptive Biotechnologies Corporation is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Adaptive Biotechnologies Corporation’s stock price was USD 17.17. Adaptive Biotechnologies Corporation’s stock price has changed by -2.34% over the past week, -10.61% over the past month and -74.38% over the last year.

About

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.55 (-3.76%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

-3.73 (-0.60%)

USD66.47B 9.89 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.23 (-0.97%)

USD58.90B 27.78 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

-5.13 (-3.17%)

USD39.21B 5.08 5.67
BGNE BeiGene Ltd

+14.52 (+6.13%)

USD24.26B N/A N/A
SGEN Seagen Inc

+0.51 (+0.38%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

-0.36 (-1.04%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
RPRX Royalty Pharma plc

-0.66 (-1.65%)

USD17.17B 20.75 11.89

ETFs Containing ADPT

Symbol Name Weight Mer Price(Change) Market Cap
PBI:CA Purpose Fund Corp. - Purp.. 0.00 % 0.75 %

-0.07 (-0.17%)

USD0.03B
PBI-B:CA Purpose Fund Corp. - Purp.. 0.00 % 0.79 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.81% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.81% 4% F 2% F
Trailing 12 Months  
Capital Gain -74.38% 20% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -74.38% 20% F 9% F
Trailing 5 Years  
Capital Gain 115.43% 77% C+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 115.43% 77% C+ 76% C
Average Annual (5 Year Horizon)  
Capital Gain 572.08% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 572.08% 98% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,011.97% 3% F 2% F
Risk Adjusted Return 56.53% 87% B+ 76% C
Market Capitalization 2.47B 90% A- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.96 19% F 21% F
Price/Book Ratio 5.78 22% F 22% F
Price / Cash Flow Ratio -16.52 78% C+ 81% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.71% 81% B- 37% F
Return on Invested Capital -23.25% 74% C 27% F
Return on Assets -11.47% 82% B- 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.60 38% F 23% F
Short Percent 3.47% 59% F 43% F
Beta 0.37 85% B 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector